Phase 2Recruiting

Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells (MSV_LE)

Phase II, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate Safety and Efficacy of Mesenchymal Stem Cells (MSV-allo) in the Treatment of Lupus Nephritis

Sponsor
Red de Terapia Celular (Industry)
Enrollment
20 planned
Conditions
Lupus Nephritis; Lupus Erythematosus
Interventions
Mesenchymal stem cells (MSC); Placebo
Ages
adults, older adults
Registry
NCT03673748, EUCTR2022-000243-80

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to evaluate the safety and efficacy of mesenchymal stem cells (MSCs) obtained from bone marrow for the treatment of adults with active proliferative lupus nephritis. The objective of this study is to evaluate the efficacy of mesenchymal stem cells (MSCs) in achieving a full or partial response in the treatment of Lupus Nephritis (LN) during its induction period.

Primary outcomes

  • Proportion of patients who have achieved complete response
  • Proportion of patients who have achieved partial response

History

  1. Study completion expected

  2. Primary completion expected

  3. Last registry update

  4. Started

  5. Registered